• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Nivolumab Effective in Peviously Treated RCC Patients

Article

The authors however cautioned that we still lack an understanding of biomarker-driven patient selection for PD-1 and PD-L1 agent. Adequate knowledge of the mechanism of action of these immuno-oncology agents could help optimize therapy, they add.

After a median follow-up of 45 months, the anti—PD-1 antibody nivolumab showed benefit in a majority of patients who had previously received 1 to 5 treatments for renal cell carcinoma, according to a report published online March 23 in the Journal of Clinical Oncology.

The previously treated cohort included 71% who had received 2 prior systemic treatments and 44% who had received three or more prior treatments for renal cell carcinoma. Out of the total 34 patients, 10 (29%) had objective responses, 9 (27%) had stable disease for at least 24 weeks, 2 (6%) had stable disease for at least 48 weeks, and 3 patients (9%) had unconventional immune-related responses, which can include reduction in target lesions in the presence of new lesions or regression after initial progression.

Complete article on Oncology Practice: http://bit.ly/18WV9bo

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.